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2019 Novel Coronavirus (2019-nCoV) is an emerging infectious disease closely related to MERS-CoV 
and SARS-CoV that was first reported in Wuhan City, Hubei Province, China in December 2019. As of 
January 2020, cases of 2019-nCoV are continuing to be reported in other Eastern Asian countries as 
well as in the United States, Europe, Australia, and numerous other countries. An unusually high vol-
ume of domestic and international travel corresponding to the beginning of the 2020 Chinese New Year 
complicated initial identification and containment of infected persons. Due to the rapidly rising number of 
cases and reported deaths, all countries should be considered at risk of imported 2019-nCoV. Therefore, 
it is essential for prehospital, clinic, and emergency department personnel to be able to rapidly assess 
2019-nCoV risk and take immediate actions if indicated. The Identify-Isolate-Inform (3I) Tool, originally 
conceived for the initial detection and management of Ebola virus and later adjusted for other infectious 
agents, can be adapted for any emerging infectious disease. This paper reports a modification of the 3I 
Tool for use in the initial detection and management of patients under investigation for 2019-nCoV. After 
initial assessment for symptoms and epidemiological risk factors, including travel to affected areas and 
exposure to confirmed 2019-nCoV patients within 14 days, patients are classified in a risk-stratified sys-
tem. Upon confirmation of a suspected 2019-nCoV case, affected persons must immediately be placed 
in airborne infection isolation and the appropriate public health agencies notified. This modified 3I Tool will 
assist emergency and primary care clinicians, as well as out-of-hospital providers, in effectively managing 
persons with suspected or confirmed 2019-nCoV. [West J Emerg Med. 2020;21(2):X-X.]
Disclaimer: Due to the rapidly evolving nature of this outbreak, 
and in the interests of rapid dissemination of reliable, actionable 
information, this paper went through expedited peer review. 
Additionally, information should be considered current only at the 
time of publication and may evolve as the science develops. On 
February 11, 2020, the World Health Organization renamed the 
virus COVID-19.
INTRODUCTION
2019 Novel Coronavirus (2019-nCoV) is a novel respiratory 
disease first reported in Wuhan, Hubei Province, China in 
December 2019.1 Chinese health officials were originally 
investigating a sudden increase in cases of pneumonia which 
were later determined to be linked to 2019-nCoV. While most 
cases originated within mainland China, the disease spread to 
neighboring countries including Taiwan, Thailand, South Korea, 
and Japan, and later to the United States, Europe, and Australia. 
A near real-time updated tracking website for cases and locations 
worldwide, along with reported deaths is available.2
Chinese health authorities have sequenced 2019-nCoV and 
freely shared its genetic profile online.3,4 Additionally, on January 
28, 2020, an Australian laboratory reported growing the virus from 
a patient sample. As of January 30, 2020, there have been at least 
9,776 persons infected and 213 verified deaths.2 These numbers 
are likely underestimates due to the limited information available 
regarding incubation time, transmissibility, and virus origin. The 
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What do we already know about this issue?
2019 Novel Coronavirus (2019-nCoV) is a 
rapidly spreading infectious disease closely 
related to severe acute respiratory syndrome 
(SARS)-CoV and Middle East respiratory 
syndrome (MERS)-CoV, first detected in late 
2019 in Wuhan, China.
What was the research question?
Investigators adapted the “Identify, Isolate, 
Inform” (3I) Tool for use in suspected cases of 
2019-nCoV. 
What was the major finding of the study?
A novel 2019-nCoV 3I Tool is designed for 
frontline clinicians in the management of 
suspected patients. 
How does this improve population health?
This 2019-nCoV 3I adaptation will aid 
healthcare providers most likely to encounter 
the disease in the containment and effective 
treatment of patients.
age distribution of these verified deaths is currently not available. 
One preliminary, small-scale study of 41 patients in Wuhan 
China, reported 6 deaths (15% mortality) with a median age of 
49.0 years.5 Additionally, transmission of the virus has reportedly 
occurred in healthcare facilities in Wuhan City, raising concerns of 
spread to healthcare workers, as was seen during prior outbreaks 
of the novel coronaviruses, Middle Eastern Respiratory Syndrome 
(MERS) and Severe Acute Respiratory Syndrome (SARS). Due to 
the dynamic nature of the outbreak, exposure criteria may change 
depending on where new cases of 2019-nCoV are detected, 
the degree of transmissibility, and when additional information 
regarding the origin of the virus is discovered and reported.
On January 15, 2020, the Centers for Disease Control and 
Prevention (CDC) confirmed the first known imported case 
of 2019-nCoV in the US state of Washington. The patient had 
recently returned from Wuhan City, where he likely contracted 
the disease. Chicago health authorities reported a second US case 
on January 24, 2020. This was quickly followed by additional 
imported cases reported in Orange and Los Angeles Counties, 
California on January 26, 2020. Additional suspected cases 
continue to be evaluated. On January 30, 2020, the CDC reported 
the first local transmission in the US between members in a 
household. On the same day, the World Health Organization 
declared 2019-nCoV to be a Public Health Emergency of 
International Concern (PHEIC).6  On January 31, 2020, the US 
Department of Health and Human Services declared coronavirus a 
public health emergency.7
Healthy individuals and those with mild illness may 
be asymptomatic, while others may have more pronounced 
symptoms of fever or lower respiratory illness. Upon 
identification of a suspected patient, that individual should 
immediately be isolated with airborne precautions. Further work-
up and laboratory confirmation can then proceed. Emergency 
physicians (EPs), emergency medical services (EMS) personnel, 
and other healthcare workers who encounter patients with 
suspected 2019-nCoV infection must inform the appropriate 
authorities, including but not limited to hospital infection control 
and local or state public health agencies.
Healthcare workers must follow on-going developments 
related to the outbreak, especially new information concerning 
detection and management.8,9  The 3I Tool outlined in this paper 
is consistent with current US CDC guidelines and can be applied 
in a variety of settings such as those in emergency departments, 
urgent-care clinics, physicians’ offices, and prehospital settings. 
This paper will first briefly review 2019-nCoV and then present 
the novel 2019-nCoV 3I Tool as modified from its initial 
conception for Ebola virus disease 10,11 and later adapted for 
measles,12 MERS,13 mumps,14 Zika virus disease,15 hepatitis A,16 
pertussis,17 and scabies.18 
CLINICAL PRESENTATION
Signs and Symptoms
Coronavirus 2019-nCoV infection commonly presents 
with signs and symptoms of pneumonia or as a nonspecific 
lower respiratory illness, with coughing or difficulty breathing 
accompanied by fever.5,19,20 Fever and cough constitute the most 
common presentations. However, patients may have other 
respiratory symptoms, sore throat, nasal congestion, malaise, 
myalgia, and headache. Bilateral infiltrates may be seen on chest 
X-ray. Severe cases may present with sepsis and even shock. 
Conversely, some patients may present as only mildly ill or 
asymptomatic altogether.21 To date, patients with underlying 
medical conditions and the elderly are more likely to become 
severely ill, require hospitalization, and ultimately die.22 Early 
predictions for incubation time are between 2 and 14 days, based 
on data from similar coronaviruses. The 14-day criterion for 
epidemiological risk assumes the longest estimated incubation 
time.23 In addition, the World Health Organization (WHO) has 
created its own interim case definition.24
Disease Characteristics 
By definition, the main features of a novel virus, for 
example, how it is transmitted, will not be immediately known. 
However, as with the development of any 3I Tool, it is essential 
to understand specific characteristics of the disease. In the 
case of a novel virus such as 2019-CoV, this is challenging 
since information is rapidly evolving and the science is not 
yet fully understood. It is possible that the virus will undergo 
mutations over time that could substantially change its 
Articles in Press 3 Western Journal of Emergency Medicine
Koenig et al. The Identify-Isolate-Inform (3I) Tool Applied to a Novel Emerging Coronavirus
Table 1. Key disease features and implications.
Scenario Special Considerations
Natural vs. human-generated (e.g., terrorism, industrial incident) Law enforcement in addition to public health investigation; 
crime scene investigation
Contagion vs. contaminant/toxin vs. neither Mode of transmission; PPE type
Transmissibility from person to person (i.e., R0) PPE requirements; need for declaration of PHEIC, need for surge 
capacity
Potential for mutations Need for monitoring and updates on public health management 
guidance
Sensitivity and specificity of testing Strategies for testing method and location (point-of-care, 
regional, national)
Contagious prior to symptom onset Amenable to quarantine; types of public health interventions 
needed to prevent spread
PHEIC, Public Health Emergency of International Concern; PPE, personal protective equipment; R0, Basic Reproduction Number: a 
mathematical prediction of disease contagiousness.
features. Nevertheless, an appreciation of the key concepts 
that drive evidence-based management is beneficial (Table 1).  
Management guidance will likely change over time.
With the initial discovery of a new potential public health 
threat, it will likely be unclear how patients become sick. For 
example, rather than a contagion, there could be a contaminant 
or a toxin responsible for signs and symptoms. In this case, 
the possibility of an environmental toxin in the Wuhan Market 
was a consideration early on when limited to no human-to-
human transmission was reported. The mode of transmission 
has implications for the types of personal protective equipment 
(PPE) needed to protect healthcare providers in the prehospital, 
clinic, and hospital settings.25 In addition, patients may need 
decontamination after exposure to certain toxins.26
Another important consideration for application of the 3I 
Tool is whether the disease is contagious prior to symptom onset 
(like measles) or only after symptoms develop (like Ebola). A 
January 30, 2020 letter to the New England Journal of Medicine 
describes a purported confirmed instance of transmission from an 
asymptomatic individual. Researchers state that, before symptom 
onset, the primary case infected two individuals, one of which 
infected two additional colleagues.27 Subsequent investigation 
suggested that the source patient did have mild symptoms and 
had taken an antipyretic, calling this reported asymptomatic 
transmission into question.
While quarantine may not be feasible and can have 
unintended consequences,28,29,30 it is a public health tool that 
can be considered in cases when disease is transmissible before 
symptom onset.30 Conversely, if a disease is known not to be 
transmissible prior to symptom onset, asymptomatic exposed 
patients must be monitored, but do not require quarantine or 
isolation unless they develop symptoms.
Initially, it may be unclear whether an infectious agent 
occurred naturally or was deliberately or accidentally released. In 
this case, a BSL-4 laboratory studying coronaviruses was located 
approximately 32 kilometers away from the market where initial 
exposures were felt to occur.31 Recall that in 2001, the anthrax 
letter attacks were initially thought to be naturally occurring. 
Once determined to be bioterrorism, management of the event 
was similar to that for a chemical exposure with a sudden impact, 
defined scene, and need for a rapid response and decontamination 
on site. This differed from the WHO’s modeling predicting an 
aerosolized release that would result in an incubation period with 
100,000 or more persons exposed rather than the 22 people who 
contracted anthrax in 2001.32 By understanding the key features 
of a novel disease, healthcare workers can take evidence-based 
measures to protect themselves, optimize individual patient 
management, and prevent further disease spread. 
Transmission
It is currently unclear how 2019-nCoV is spread, but it 
is suspected to be transmitted through contact with infected 
respiratory secretions, like other known coronaviruses. There 
are instances of sustained human-to-human transmission across 
generations of cases, especially near the epicenter in Wuhan 
City.21 Current evidence suggests that close contact with an 
infected person is a major factor in disease transmission. CDC 
defines “close contact”33 as being in or within two meters of 
an area with a confirmed patient or being directly exposed 
to infectious secretions without appropriate PPE. Healthcare 
facilities in China have reported spread from person to person. 
In addition, some mildly ill or potentially even asymptomatic 
patients may have a higher chance of spreading the disease to 
others as they may be less likely to seek medical care.34 The 
possibility that patients may be infectious prior to symptom onset 
further compounds the difficulty of containing the virus and 
effectively preventing transmission.
The current majority of 2019-nCoV cases have been 
within China and its bordering countries.2 Persons with recent 
travel (within 14 days) to Wuhan City or another region with 
widespread disease, or exposure to a patient under investigation, 
are considered to have an epidemiologic risk factor and should 
be assessed for signs and symptoms of a viral illness such as 
fever and respiratory symptoms. Coronavirus is a zoonotic virus 
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that is transmitted to humans via contact with infected animals. 
Preliminary reports suggest the disease may have originated in 
a seafood and live animal market in Wuhan City, but it is still 
unknown how or whether such transmission occurred.
Work-Up
Clinicians working with local public health departments 
must arrange to have specimens from patients under 
investigation (PUIs) sent to the CDC laboratory. At this time, 
the CDC has the only laboratory that can definitively test for 
2019-nCoV, though laboratory testing capacity is being rapidly 
expanded. Polymerase chain reaction (PCR) assays conducted 
on samples from a patient’s upper and lower respiratory tracts 
will be used to confirm potential cases. In addition, serum 
antibody titers can be analyzed for confirmation of infection or 
evidence of immunity. Up-to-date information about the needed 
specimens and handling requirements to test for 2019-nCoV are 
available on the CDC website.35
Differential Diagnosis
Like other related coronaviruses, patients with 2019-nCoV 
frequently present with non-specific symptoms resembling that of 
influenza. Physicians may consider differential diagnoses related 
to a wide variety of respiratory infections. In order to relate these 
symptoms to 2019-nCoV, it is imperative that the identification of 
a potential exposure event (epidemiologic risk factor) within 14 
days of symptom onset is made so that a more focused work-up 
for 2019-nCoV can be completed.  Although the likelihood of co-
infection of 2019-nCoV and another respiratory virus is thought 
to be low, a positive finding of another respiratory pathogen does 
not exclude the diagnosis of 2019-nCoV. Many commercially 
available respiratory panels include “coronavirus” in the results, 
but neither a positive nor a negative finding on these panels 
should be used to include or exclude a diagnosis of 2019-nCoV.
Treatment
Supportive care with appropriate infection control is the 
mainstay of current CDC treatment guidelines for 2019-nCoV.  
There are not yet any approved antiviral treatments for 2019-
nCoV. Emergency Use Authorizations (EUA) for compassionate 
use cases may be forthcoming from the US federal government 
for normally unapproved treatments. Supportive treatment 
predominantly includes respiratory support, hydration, and 
antipyretics. General treatment for severe cases should focus on 
the preservation of vital organ function. In the future, antiviral 
medications may be available. If a secondary bacterial infection 
such as pneumonia develops, targeted antibiotics are indicated. 
Prevention
Prevention of 2019-nCoV transmission, like any other 
infectious agent, involves minimizing risk of exposure. Vaccines 
are under accelerated development and may be useful in the 
future for post-exposure prophylaxis. Healthcare personnel are at 
increased risk and should practice standard, droplet, and airborne 
precautions when encountering an infected person, a PUI, or 
any symptomatic close contacts. Healthcare workers handling 
specimens should also adhere to CDC guidelines and should not 
attempt to perform any virus isolation or characterization. 
Fever screening has been implemented at numerous airports, 
including major international hubs within Asia and the US. The 
efficacy of this intervention is not well documented, however, as 
some infected persons may be afebrile and disease transmission 
might occur prior to symptom onset.27 In addition, people can 
artificially lower their temperature readings, e.g., by applying ice 
to their foreheads.
Patient Disposition
As outlined above, admission criteria for 2019-nCoV are 
similar to that of other patients. If patients do not meet medical 
criteria for hospitalization, they may be discharged home with 
isolation precautions and continued observation. EPs must notify 
local public health authorities so appropriate monitoring and 
community protective measures can be instituted.
Identify-Isolate-Inform
The Identify-Isolate-Inform (3I) Tool was initially developed 
for Ebola virus disease 10,11 and later adapted for measles,12 
MERS,13 mumps,14 Zika virus disease,15 hepatitis A,16 pertussis,17 
and scabies.18  This novel tool for suspected 2019-nCoV patients 
(Figure 1) provides frontline clinicians with a simple algorithm to 
manage an emerging disease. Identification of exposed patients 
with an epidemiologic risk factor within 14 days of symptom 
onset is a crucial first step. An automatic prompt in the electronic 
health record can be useful in assisting clinicians with early 
identification of patients at risk. Case definitions promulgated by 
the WHO24 and CDC33 provide useful comprehensive definitions 
that have been incorporated into the 3I Tool. The 2019-nCoV 
Tool provides an accurate, summarized algorithm to immediately, 
and effectively manage suspected patients until additional 
resources can be consulted.  
Patients who do not have an exposure risk or any symptoms 
may be triaged normally. However, before making patient 
contact, providers must first apply the Vital Sign Zero concept.36 
Vital Sign Zero is a preliminary, non-contact assessment (i.e., 
performed prior to touching a patient to take traditional vital 
signs) to first determine whether specific PPE is indicated 
before the examination commences. By taking the additional 
time to complete this assessment, risk of exposure and further 
transmission can be minimized.
Following identification of patients with clinical features 
and an established epidemiologic risk, isolation should occur 
immediately. Patients should don a surgical mask before being 
placed in an airborne infection room, if available. Any healthcare 
staff entering the room should don a NIOSH-certified N95 
respirator (or equivalent), eye protection, gloves, and a gown, as 
per CDC recommendations. Further patient contact and sample 
collection may then proceed. A list of all individuals (staff or 
other patients) who were in close contact with the individual 
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Figure 1. Koenig’s Identify-Isolate-Inform Tool adapted for 2019-nCoV.
  
  
              
• Don/Doff patient-contact PPE:
N95 respirator (or equivalent), gloves, 
gown, and eye shield protection
• Place surgical mask on patient
In Hospital Settings:
• Transfer to airborne infection isolation
• Post “Special Precautions” on door 
(standard, contact, and airborne 
precautions + face shield/eye protection)
• Hospital Infection Prevention
• Local and State Health Department
• Other authorities per local protocol 
ISOLATE 
Meets Criteria 1,2, or 3:
1. Close contact† with a 
laboratory-confirmed 
patient
2. History of travel from 
Hubei Province, China
3. History of travel from 
mainland China
Within 2 m (6 ft) of known infection without 
appropriate PPE for an extended period of time or
while directly exposed to secretions
Update as additional regions/countries with 
documented local transmission are added
INFORM 
Matches Exposure Criteria:
1. Fever‡ or signs/ 
symptoms of lower 
respiratory illness§
2. Fever‡ and signs/ 
symptoms of lower 
respiratory illness§
3. Fever‡ and signs/ 
symptoms of lower 
respiratory illness§
requiring hospitalization
Subjective or confirmed (≥38ºC/100.4ºF). Fever 
may be absent in young, elderly, immunosuppressed, 
or those taking antipyretics. May also present with 
pneumonia or influenza-like symptoms.
Includes coughing and shortness of breath
OR 
 
 
SIGNS AND SYMPTOMS 
Identify – Isolate – Inform
Clinical Evaluation and Management of Patients Under Investigation 
(PUIs) for Coronavirus (2019-nCoV)
Information Current as of January 31, 2020. Criteria may change over time. 
IDENTIFY 
Exposure + Symptoms 
EXPOSURE 
WITHIN 14 DAYS   
The Identify-Isolate-Inform tool was conceived by Dr. Kristi L. Koenig, County of San Diego EMS Medical Director & Professor Emerita, UC Irvine 
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§ * 
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while in the treatment facility should be started and maintained to 
assist with the possibility of contact tracing. 
Following isolation, physicians should immediately inform 
the appropriate authorities. Patients who do not meet medical 
criteria for admission can be isolated at home during the 
evaluation phase.37 Health department officials can help prevent 
transmission in isolated patients by providing in-home monitoring 
and implementing appropriate exposure-control measures.
Prehospital EMS Management
Providers in the prehospital setting who have a high 
likelihood of encountering 2019-nCoV patients, such as those 
near international ports of entry, should adhere to established 
exposure control guidelines.38Along with appropriate PPE, 
providers should also carry thermometers to quantify any 
fever. In the US, providers should contact the appropriate CDC 
quarantine station upon isolation of infected or suspected patients, 
especially those from Wuhan, China or other regions with 
widespread disease, who report symptoms in the last 14 days. As 
for other infectious diseases, assessing travel history is essential. 
Dispatch protocols have been instituted to facilitate identification 
of callers to 911 or the country-equivalent emergency number 
prior to prehospital personnel arrival.39 In addition, CDC has 
promulgated EMS guidelines for prehospital PPE, transportation 
of PUIs, vehicle decontamination, and 911 Public Safety 
Answering Points (PSAPs) for 2019-nCoV.40
CONCLUSION
2019-nCoV is an emerging infectious disease with rapidly 
evolving features, the full scope of which will be defined 
over time. Prior outbreaks of coronaviruses can help inform 
needed actions in the short term to assist with both treatment of 
individual patients and prevention of global disease spread. This 
adaptation of the Identify-Isolate-Inform Tool serves as a resource 
for healthcare workers who need to make clear, rapid assessments 
when confronted with potential patients. The concise nature 
of the 2019-nCoV 3I Tool allows for the rapid and effective 
management of a novel disease by healthcare providers. 
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